BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND MLH1, COCA2, 4292, ENSG00000076242, hMLH1, FCC2, HNPCC2, P40692, MGC5172, HNPCC AND Prognosis
62 results:

  • 1. Expression of EGFR, PD-L1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high-grade serous tubo-ovarian carcinoma.
    Nikas IP; Park SY; Song MJ; Lee C; Ryu HS
    Diagn Cytopathol; 2024 Feb; 52(2):69-75. PubMed ID: 37937321
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Case report: Remarkable response to a novel combination of mitotane, etoposide, paraplatin, and sintilimab in a patient with metastatic adrenocortical carcinoma.
    Weng Y; Wang L; Wang XY; Fan XX; Yan L; Li ZH; Zhang SL
    Front Endocrinol (Lausanne); 2023; 14():1115893. PubMed ID: 37745701
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. DAXX, ATRX, and MSI in PanNET and Their Metastases: Correlation with Histopathological Data and prognosis.
    Gisder DM; Overheu O; Keller J; Nöpel-Dünnebacke S; Uhl W; Reinacher-Schick A; Tannapfel A; Tischoff I
    Pathobiology; 2023; 90(2):71-80. PubMed ID: 35691289
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Complete Response of a Patient With a Mismatch Repair Deficient Aggressive Pituitary Adenoma to Immune Checkpoint Inhibitor Therapy: A Case Report.
    Shah S; Manzoor S; Rothman Y; Hagen M; Pater L; Golnik K; Mahammedi A; Lin AL; Bhabhra R; Forbes JA; Sengupta S
    Neurosurgery; 2022 Aug; 91(2):e51-e56. PubMed ID: 35544035
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The clinical features and management of Lynch syndrome-associated ovarian cancer.
    Ran X; Jing H; Li Z
    J Obstet Gynaecol Res; 2022 Jul; 48(7):1538-1545. PubMed ID: 35478369
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Correlation of mismatch repair deficiency with clinicopathological features and programmed death-ligand 1 expression in thyroid carcinoma.
    Qiao PP; Tian KS; Han LT; Ma B; Shen CK; Zhao RY; Zhang Y; Wei WJ; Chen XP
    Endocrine; 2022 Jun; 76(3):660-670. PubMed ID: 35366156
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Evaluation of biomarkers, genetic mutations, and epigenetic modifications in early diagnosis of pancreatic cancer.
    Rah B; Banday MA; Bhat GR; Shah OJ; Jeelani H; Kawoosa F; Yousuf T; Afroze D
    World J Gastroenterol; 2021 Sep; 27(36):6093-6109. PubMed ID: 34629822
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Hereditary pancreatic cancer.
    Abe K; Kitago M; Kitagawa Y; Hirasawa A
    Int J Clin Oncol; 2021 Oct; 26(10):1784-1792. PubMed ID: 34476650
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Expression of CD117, CK17, CK20, MUC4, villin and mismatch repair deficiency in pancreatic intraductal papillary mucinous neoplasm.
    Detlefsen S; Jakobsen M; Nielsen MFB; Klöppel G; Mortensen MB
    Pathol Res Pract; 2021 Jan; 217():153312. PubMed ID: 33341087
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Micronuclei Formation upon Radioiodine Therapy for Well-Differentiated Thyroid cancer: The Influence of DNA Repair Genes Variants.
    S Santos L; M Gil O; N Silva S; C Gomes B; C Ferreira T; Limbert E; Rueff J
    Genes (Basel); 2020 Sep; 11(9):. PubMed ID: 32957448
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: study of 13 cases comparing ductal pancreatic carcinoma and review of the literature.
    Hrudka J; Lawrie K; Waldauf P; Ciprová V; Moravcová J; Matěj R
    Virchows Arch; 2020 Nov; 477(5):687-696. PubMed ID: 32424767
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.
    Zhu J; Ke G; Bi R; Wu X
    J Surg Oncol; 2020 Sep; 122(3):538-546. PubMed ID: 32396667
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Long Survival and Prolonged Remission after Surgery and Chemotherapy in a Metastatic Mismatch Repair Deficient Pancreatic Neuroendocrine Carcinoma with mlh1/PMS2 Immunodeficiency and Minimal Microsatellite Shift.
    Vanoli A; Perfetti V; Furlan D; Neri G; Viglio A; Sessa F; Martino M; Di Sabatino A; Solcia E; La Rosa S
    Endocr Pathol; 2020 Dec; 31(4):411-417. PubMed ID: 32388775
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Frequency of mismatch repair deficiency in pancreatic ductal adenocarcinoma.
    Ahmad-Nielsen SA; Bruun Nielsen MF; Mortensen MB; Detlefsen S
    Pathol Res Pract; 2020 Jun; 216(6):152985. PubMed ID: 32360245
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Immunohistological evaluation of mismatch repair deficiency in pancreatic ductal adenocarcinoma treated with surgical resection.
    Otsuka H; Murakami Y; Uemura K; Kondo N; Nakagawa N; Okada K; Seo S; Takahashi S
    J Hepatobiliary Pancreat Sci; 2020 Jul; 27(7):421-428. PubMed ID: 32219999
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. mlh1 Is a Prognostic Biomarker for Serous Ovarian cancer Treated With Platinum- and Taxane-based Chemotherapy.
    Kawashima N; Yoshida H; Miwa M; Fujiwara K
    Anticancer Res; 2019 Oct; 39(10):5505-5513. PubMed ID: 31570444
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Genetic polymorphisms in
    Si W; Kang S; Sun H; Chen J; Cao S; Li Y
    Int J Gynecol Cancer; 2019 Sep; 29(7):1148-1155. PubMed ID: 31273068
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Methylation of tumour suppressor genes associated with thyroid cancer.
    Botezatu A; Iancu IV; Plesa A; Manda D; Popa O; Bostan M; Mihaila M; Albulescu A; Fudulu A; Vladoiu SV; Huica I; Dobrescu R; Anton G; Badiu C
    Cancer Biomark; 2019; 25(1):53-65. PubMed ID: 31006665
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Comprehensive cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic cancer Patients Receiving Neoadjuvant Treatment.
    Yoon KA; Woo SM; Kim YH; Kong SY; Lee MK; Han SS; Kim TH; Lee WJ; Park SJ
    Gut Liver; 2019 Nov; 13(6):683-689. PubMed ID: 30970447
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma.
    Schmoeckel E; Hofmann S; Fromberger D; Rottmann M; Luthardt B; Burges A; Jeschke U; Kirchner T; Lax SF; Mayr D
    Virchows Arch; 2019 May; 474(5):599-608. PubMed ID: 30734108
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4.